NasdaqCM - Nasdaq Real Time Price ? USD Entero Therapeutics, Inc. (ENTO) Follow Compare 0.6140 +0.0343 (+5.72%) As of 12:17 PM EDT. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial complianceBOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced its entry into a bindi GlobeNewswire ? last month ENTO +5.72% Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) advising that, because the Company failed to timely file its Quarterly Report on Form 10-Q fo GlobeNewswire ? last month ENTO +5.72% Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today released a letter from James Sapirstein, the Company’s Chairman and CEO, to provide stockholders with a business update. LETTER FROM OUR CHAIRMAN AND CHIEF EXECUTIVE OFFICER To my fellow stockholders, We are ma GlobeNewswire ? 2 months ago ENTO +5.72% Entero Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds BOCA RATON, Fla., July 11, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (“Entero” or the “Company”) (NASDAQ: ENTO), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has entered into agreements with certain holders of its existing warrants exercisable for 1,762,674 shares of its common stock, in the aggregate, to exercise their warrants at a reduced exercise price of $1.09 pe GlobeNewswire ? 3 months ago ENTO +5.72% Entero Therapeutics Announces Abstract on Celiac Disease Research Accepted for Presentation at the 20th International Celiac Disease Symposium Oral presentation will showcase novel VCIEL scale for assessing small intestinal mucosal health in Celiac DiseaseBOCA RATON, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that an abstract has been accepted for oral presentation at the 20th International Celi GlobeNewswire ? 3 months ago ENTO +5.72% Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease New VCIEL scale provides a more sensitive and quantitative metric of small intestinal health for monitoring Celiac Disease severity and treatment efficacy Special editorial highlights the potential importance of VCIEL for CeD research and clinical trials BOCA RATON, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapi GlobeNewswire ? 3 months ago ENTO +5.72% Entero Therapeutics to Present Corporate Update at 2024 BIO International Convention Late clinical-stage company to provide update on Phase 3 treatment for celiac diseaseBOCA RATON, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc. (formerly First Wave BioPharma, Inc.) (Nasdaq: ENTO) (“Entero” or the “Company”), a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the 2024 BIO International Convention which will be held June 3-6, 20 GlobeNewswire ? 4 months ago ENTO +5.72% Entero Therapeutics Presents Two Posters on Celiac Disease Research at the 2024 Digestive Disease Week (DDW) Conference Presentations highlight new VCIEL scale to measure small intestinal mucosal health and research from rich database of latiglutenase Phase 2 clinical trialsBOCA RATON, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, yesterday presented two posters on celiac disease research at GlobeNewswire ? 4 months ago ENTO +5.72% Performance Overview Trailing total returns as of 10/17/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return ENTO S&P 500 YTD -85.38% +22.91% 1-Year -91.18% +34.04% 3-Year -99.99% +31.11%
